Subscribe to RSS



Apple Inc. (NASDAQ:AAPL) Sad on Sales Forecast Reduced On Weak Demand – AAPL, BBRY, CSCO, EMC, HPQ

Apple Inc. (NASDAQ:AAPL) expect lower than anticipated demand in previous quarter, declares an analyst in cutting his earnings and revenue predict for the iPhone maker.

Apple is aim to declare results for its fiscal Q2 ended in late March on April 23 following the market close. In a research note announced on Friday, RBC Capital Markets analyst Amit Daryanani declares the firm experienced weaker demand for its flagship iPhone and iPad products.

Daryanani predicts revenue to increase 5.3 percent to $41.2B, other than analysts on average predict 8.9 percent growth, to $42.6B.

Shares of Apple Inc. (NASDAQ:AAPL) traded at $429.80 by plunging -1.04% with price volatility of 1.58% for a week and 1.94% for a month plus price volatility’s Average True Range for 14 days was 9.15 and its beta stands at 1.00 times.

Stocks after opening at $434.15 hit high price of $434.15 and on last session stock held volume of 8.53 million shares which was unexpectedly lower than its average volume of 15.28 million shares.

Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 1.54 as current ratio. The Company had total cash at hand $39.82 billion and a book value per share as $135.62 in the most recent quarter.

While investors who viewing AAPL against other stocks with the reference of profit margin that are Research In Motion Ltd (NASDAQ:BBRY) having profit margin -6.73%, Cisco Systems, Inc. (NASDAQ:CSCO) with 19.72% profit margin, EMC Corporation (NYSE:EMC) having 18.26% profit margin and Hewlett-Packard Company (NYSE:HPQ) having profit margin of -10.86%.


Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here

0 comments

Other articlesgo to homepage

Over-Surged Session Stocks: GW Pharmaceuticals PLC (Nasdaq:GWPH), IntriCon Corp (Nasdaq:IIN), Idera Pharmaceuticals Inc (Nasdaq:IDRA), Intercept Pharmaceuticals Inc (Nasdaq:ICPT), Epizyme Inc (Nasdaq:EPZM)

Over-Surged Session Stocks: GW Pharmaceuticals PLC (Nasdaq:GWPH), IntriCon Corp (Nasdaq:IIN), Idera Pharmaceuticals Inc (Nasdaq:IDRA), Intercept Pharmaceuticals Inc (Nasdaq:ICPT), Epizyme Inc (Nasdaq:EPZM)

Shares of GW Pharmaceuticals plc (Nasdaq:GWPH) are trading on different levels, after research firm Morgan Stanley initiated coverage on the company with an Overweight rating and a price target of $103.00 per share. GWPH stock is currently trading for about $63.61, up $17.57 (or +38.16%), with a volume of 4,988,786 shares traded so far. The

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

On-top Session Stocks: BioFuel Energy Corp (Nasdaq:BIOF), LiveDeal Inc (Nasdaq:LIVE), Insteel Industries Inc (Nasdaq:IIIN), SGOCO Group Ltd (Nasdaq:SGOC), SanDisk Corp (Nasdaq:SNDK)

Shares of BioFuel Energy Corp. (Nasdaq:BIOF) skyrocketed on Thursday’s market activity, currently trading for about $8.20, up $2.14 (or +35.30%), and 5,845,868 of its shares exchanged hands so far BioFuel Energy recently received a preliminary non-binding proposal, which suggested the company acquire acquire all of the equity interests in real-estate developer JBGL Capital and JBGL

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Gaining Investiture Session Stocks: Zalicus Inc (Nasdaq:ZLCS), Zogenix Inc (Nasdaq:ZGNX), Lightbridge Corp (Nasdaq:LTBR), Apricus Biosciences Inc (Nasdaq:APRI), Alliqua Inc (Nasdaq:ALQA)

Shares of Zalicus Inc. (Nasdaq:ZLCS) skyrocketed $0.32 (or +31.07%) to $1.35, following the announcement that Epirus Biopharmaceuticals, Inc., which has closed a $36 million Series B financing round, will merge with a wholly-owned subsidiary of Zalicus, to create a global biosimilar enterprise. 13,616,255 shares of Zalicus were traded on Wednesday, increased activity versus its average

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

Momentum Overcomers Session Stocks: SmartPros Ltd (Nasdaq:SPRO), Akebia Therapeutics Inc (Nasdaq:AKBA), WebMD Health Corp (Nasdaq:WBMD), bebe stores inc (Nasdaq:BEBE), Chindex International Inc (Nasdaq:CHDX)

The trading levels of SmartPros Ltd. (Nasdaq:SPRO) stock exploded on Monday’s market activity, closing at $2.99, up $0.77 (or +34.68%), and 334,315 of its shares exchanged hands during the day, a large increase on activity versus its average volume (3m) of 7,818 On intraday trading, SPRO stock reached a new 52 week high of $3.30

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Bullish Prospective Session Stocks: JAKKS Pacific Inc (Nasdaq:JAKK), Rambus Inc (Nasdaq:RMBS), Rentech Inc (Nasdaq:RTK), Oramed Pharmaceuticals Inc (Nasdaq:ORMP), UBIC Inc (Nasdaq:UBIC)

Shares of JAKKS Pacific, Inc. (Nasdaq:JAKK) soared $0.75 (or +9.96%) to $8.28, and 1,043,882 of its shares exchanged hands on Friday’s trading session. JAKKS Pacific, a leading designer and marketer of toys and consumer products, was upgraded from Market Perform to Outperform and its price target raised from $8.00 to $10.00 by brokerage firm BMO

read more

Sign Up*

Receive Our Newsletter!

 



 

 

Contacts and information

Social networks

Most popular categories

© 2014 Crown Equity Holdings Inc. All rights reserved.